Sulfonylureas (e.g., chlorpropamide, glibenclamide, glimepiride, glipizide, tolazamide, and tolbutamide) stimulate pancreatic β-cell insulin secretion and are used for the treatment of T2D [245]. This evidence concerns the gene INS and type 2 diabetes mellitus.